
Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, discusses how the new once every 2-month injectable PrEP has shown potential to increase adherence among populations with the greatest need.

Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, discusses how the new once every 2-month injectable PrEP has shown potential to increase adherence among populations with the greatest need.

Study finds little evidence to support the long-standing recommendation that women with a first-degree family relative diagnosed with breast cancer should get screened 10 years earlier.

It is time to compensate pharmacy technicians in accordance with their value.

An ASCP 2022 Annual Meeting session presenter provides an update of 6 new therapeutic agents and their appropriate use in an older adult population.

Problems such as sleep deprivation, excessive sleeping, or inability to sleep regularly may be an important factor in the transition from episodic to chronic migraines.

Pharmacy Times will be covering the American Society of Nephrology (ASN) Kidney Week, which will be gathering more than 10,000 professionals working on kidney health in Orlando, Florida.

Herpes zoster can increase the risk of stroke, especially among patients under 40 years of age, for whom the vaccine is not typically recommended.

Technicians are vital members of pharmacy teams and stepped up even more during the COVID-19 pandemic.

Pharmacy Times is gearing up for Kidney Week (Nov. 3-6) by learning about the pharmacological role of kidney care from the president of the American Society of Nephrology.

New evidence suggests that using artificial intelligence can help individualize diagnostics and protocols, including when women should get mammograms and what medications can best suit which people.

Epcoritamab is an investigational subcutaneous bispecific antibody being investigated for the treatment of adult patients with relapsed/refractory large B-cell lymphoma.

A compound often found in citrus fruits, nobiletin, could be a less toxic and more effective treatment for cholangiocarcinoma.

Chronic hypertension during pregnancy increases the risk of poor pregnancy and birth outcomes.

Last year in particular, pharmacists played a greater role in patient care with an increased workload as they connected patients, providers, and payers.

Purpose-built assisted reality solutions help streamline processes and maintain regulatory compliance from the laboratory to the factory floor.

Providers working in collaboration with pharmacists saw significantly more patients than providers who worked independently.

New dry eye disease treatment on the horizon.


Camizestrant is a next-generation oral SERD and pure Erα antagonist that has demonstrated anti-cancer activity across a range of preclinical models, including in patients with ER-activating mutations.

Pharmacy Times will be covering the American Society of Consultant Pharmacists (ASCP) Annual Meeting, which will be gathering senior care pharmacists in San Antonio, Texas.

Inflammation-based prognostic scores can be a valuable tool in assessing the overall survival of patients with intrahepatic cholangiocarcinoma.

Otilimab also inhibits the biological function of GM-CSF by blocking the interaction of GM-CSF with its cell surface receptor.

The estimation of glomerular filtration rate based on cystatin C could provide a more robust prediction of cardiovascular disease and mortality in patients.

Covis announced positive topline results for 2 new medications that can treat patients with moderate to severe stable chronic obstructive pulmonary disease.

Pharmacists can remind parents to have an EpiPen on hand and to carefully review candy after trick-or-treating.

In a panel, pharmacy technicians discuss the future of pharmacy technicians in United States, Portugal, and the United Kingdom.

New clinical outcomes from BICSTaR study indicate sustained impact of the therapy for individuals with HIV.

Results demonstrate improved progression-free survival in the overall patient population and in a prespecified biomarker subgroup of tumors with alterations in specific genes, AstraZeneca says.

Findings are encouraging for individuals with cancer who are receiving immune checkpoint inhibition treatment and want to get a third vaccine dose, investigators said.

Modifications related to final product verifications, immunizations, and remote work loom on the horizon for 2023.